What Is the Future of the COPD Market? Forecasts & Key Opportunities
According to a newly published market research report by 24LifeSciences, global Chronic Obstructive Pulmonary Disorder market was valued at USD 24.2 billion in 2025 and is projected to grow from USD 25.6 billion in 2026 to reach USD 33.3 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period.
Chronic Obstructive Pulmonary Disease (COPD) represents a group of progressive lung diseases, primarily encompassing chronic bronchitis and emphysema, characterized by persistent respiratory symptoms and airflow limitation. This irreversible condition manifests through breathlessness, chronic cough, and sputum production, significantly impacting patients' quality of life and functional capacity. The disease pathogenesis involves chronic inflammation and structural damage to airways and lung parenchyma, predominantly caused by long-term exposure to irritating gases or particulate matter, most notably from tobacco smoke and environmental pollutants. As the third leading cause of death worldwide according to World Health Organization data, COPD demands comprehensive management strategies and continues to drive substantial market growth through evolving therapeutic approaches.
Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/8978/chronic-obstructive-pulmonary-disorder-marketWhat Is the Future of the COPD Market? Forecasts & Key Opportunities
According to a newly published market research report by 24LifeSciences, global Chronic Obstructive Pulmonary Disorder market was valued at USD 24.2 billion in 2025 and is projected to grow from USD 25.6 billion in 2026 to reach USD 33.3 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.5% during the forecast period.
Chronic Obstructive Pulmonary Disease (COPD) represents a group of progressive lung diseases, primarily encompassing chronic bronchitis and emphysema, characterized by persistent respiratory symptoms and airflow limitation. This irreversible condition manifests through breathlessness, chronic cough, and sputum production, significantly impacting patients' quality of life and functional capacity. The disease pathogenesis involves chronic inflammation and structural damage to airways and lung parenchyma, predominantly caused by long-term exposure to irritating gases or particulate matter, most notably from tobacco smoke and environmental pollutants. As the third leading cause of death worldwide according to World Health Organization data, COPD demands comprehensive management strategies and continues to drive substantial market growth through evolving therapeutic approaches.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8978/chronic-obstructive-pulmonary-disorder-market
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
